Delcath Systems (NASDAQ:DCTH) Stock Breaks Above 50-Day Moving Average - What's Next?

Key Points

• Delcath shares rose above their 50-day moving average, trading as high as $20.30 versus a $15.53 average, on volume of about 3.45 million shares.
• Q3 2026 results beat expectations: earnings were $0.17 per share versus an expected $0.09 loss, and revenue was $35.1 million versus a forecast of about $26 million. The company guided to FY 2026 revenue of $115 million–$117 million, above consensus.
• Analyst sentiment is generally positive: BTIG raised its price target to $25 and kept a Buy rating; the stock carries a “Moderate Buy” consensus and an average target of $28.

Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report)'s share price crossed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $15.53 and traded as high as $20.30. Delcath Systems shares last traded at $20.27, with a volume of 3,448,393 shares trading hands.

Key Stories Impacting Delcath Systems

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: For Q3 2026, Delcath reported earnings of $0.17 per share, versus analysts’ expected loss of about $0.09, and revenue of $35.1 million, ahead of the $26.0 million consensus estimate. Article: Delcath Systems Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: The company projected FY 2026 revenue of $115 million to $117 million, above the analyst consensus of $106.2 million, and is targeting at least 36 active centers by year-end. Article: Delcath outlines 2026 revenue guidance and active-center target
• Positive Sentiment: BTIG Research raised its price target to $25 from $21 and maintained a Buy rating, signaling increased analyst confidence.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Wall Street Zen upgraded Delcath Systems from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Zacks Research lowered shares of Delcath Systems from a "strong-buy" rating to a "hold" rating in a report on Tuesday, October 6th. BTIG Research upped their price objective on shares of Delcath Systems from $21.00 to $25.00 and gave the stock a "buy" rating in a research report on Monday. HC Wainwright reaffirmed a "buy" rating and set a $32.00 price objective (up from $30.00) on shares of Delcath Systems in a report on Friday, August 7th. Finally, Weiss Ratings lowered shares of Delcath Systems from a "hold (c)" rating to a "hold (c-)" rating in a research report on Wednesday, October 28th. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Delcath Systems has an average rating of "Moderate Buy" and an average price target of $28.00.

Delcath Systems Stock Performance

The company has a market cap of $703.37 million, a PE ratio of 2,029.03 and a beta of 0.62. The firm's 50 day moving average is $15.53 and its 200-day moving average is $12.49.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported $0.17 earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.26. Delcath Systems had a return on equity of 0.46% and a net margin of 0.56%. The company had revenue of $35.10 million for the quarter, compared to analyst estimates of $25.99 million. On average, analysts predict that Delcath Systems, Inc. will post -0.17 EPS for the current year.

Institutional Trading of Delcath Systems

Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp purchased a new stake in Delcath Systems in the second quarter valued at approximately $1,362,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Delcath Systems in the first quarter worth $306,000. Kopp Family Office LLC acquired a new position in shares of Delcath Systems in the third quarter worth $450,000. Sei Investments Co. increased its holdings in Delcath Systems by 100.0% during the 1st quarter. Sei Investments Co. now owns 44,058 shares of the company's stock worth $409,000 after purchasing an additional 22,029 shares during the period. Finally, Russell Investments Group Ltd. increased its stake in shares of Delcath Systems by 31.1% during the third quarter. Russell Investments Group Ltd. now owns 88,727 shares of the company's stock worth $1,417,000 after buying an additional 21,069 shares during the period. 61.12% of the stock is owned by institutional investors and hedge funds.

Delcath Systems Company Profile

Delcath Systems, Inc is a medical technology company focused on liver-directed cancer treatments. The company develops and commercializes systems designed to deliver high concentrations of chemotherapy to the liver while limiting exposure to the rest of the body.

Its primary product in the United States is the HEPZATO KIT, a liver-directed therapy that combines the company's proprietary hepatic delivery system with melphalan hydrochloride for injection. HEPZATO is approved for the treatment of adult patients with unresectable metastatic uveal melanoma involving the liver, without extrahepatic disease or with limited extrahepatic disease that is not clinically significant.

Outside the United States, Delcath markets the corresponding system under the CHEMOSAT brand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.